Negative pressure wound closure devices and methods

Information

  • Patent Grant
  • 10575991
  • Patent Number
    10,575,991
  • Date Filed
    Thursday, March 10, 2016
    8 years ago
  • Date Issued
    Tuesday, March 3, 2020
    4 years ago
Abstract
Systems, devices, and methods of the present application can accelerate and reduce medical complications associated with healing of amputation wounds. The devices and methods utilize a compression structure and negative pressure to cause the amputation wound to preferentially close from the deepest portion of the wound to the shallowest portion.
Description
BACKGROUND OF THE INVENTION

A variety of wounds are now being treated using negative pressure wound therapy. However, many of these wounds have characteristics that limit the effectiveness of existing techniques. Wound dehiscence, in which the wound margins have substantial separation, pose significant problems in reapproximation of tissue and wound drainage. For example, there are a large number of patients undergoing amputations in the United States every year. These have different causes including traumatic injury, peripheral vascular disease, diabetes mellitus and chronic venous insufficiency. Patients with diabetic conditions, for example, often suffer from restricted blood flow that can lead to tissue necrosis at the body extremities. For patients with severe symptoms, a transmetatarsal amputation (TMA) may be recommended to remove afflicted tissue while still salvaging a portion of the foot. In many cases, a transtibial or below-knee amputation (BKA) must be performed. An important factor in the recovery of a patient from amputation is how quickly the wound can be closed. Because the gap between tissue margins can be large, the wound is manually closed by suturing. There must be ongoing attention to prevent complications such as infection, wound dehiscence, and/or ischemia. The use of an immediate post-operative prosthesis (IPOP) is commonly employed to reduce the recovery period for BKA procedures, for example.


Other examples of wounds that can be difficult to achieve approximation of the wound margins can include ulcers in which the wound opening is surrounded by tissue overlying a cavity. The undermining of the tissue surrounding the wound opening can often present problems in drainage and rapid wound closure. There are also open wounds that can occur in both the extremities and the abdominal regions in which the wound margins must rotate over a substantial distance, often up to several centimeters or more, to achieve approximation of the margins. Thus a continuing need exists for improvements in wound closure devices and methods.


SUMMARY OF THE INVENTION

This disclosure relates to embodiments of negative pressure wound closure devices, systems, and methods for wounds resulting from amputation or other open wounds having non-aligned wound margins. In preferred embodiments, the system includes a negative pressure source and a collapsing structure that is placed on the wound to provide directed preferential closure. The collapsing structure can include embodiments in which a compressive force is imparted to tissue surrounding the wound or to tissue on the sides of a wound opening that is operative to assist in the closure of a wound cavity. Thus, the collapsing structure can include, be attached to, or operate in conjunction with, a compression structure that operates to apply a force to the tissue adjoining an open wound to move a wound margin to a more closed position. In a preferred embodiment, a collapsing compression structure includes a number of cells separated by rigid or semi-rigid membranes that are hinged together at joints. The structure changes conformation during a procedure to facilitate closure of the wound. The structure, in combination with the application of negative pressure, exerts a force to the wound to facilitate closure of the wound from the deepest internal point. The structure can be rigid, or alternatively, be pre-stressed to exert a compression force on the wound to more quickly bring the wound margins together.


The device can be used without any sutures in cases where the skin on opposite sides of the wound is sufficiently aligned. Alternatively, sutures can be used to provide alignment in the case of a wound where the margins and/or the overlying skin are not well aligned or are not amenable to restructuring to make them so aligned.


Wound closure of open wounds in which the wound margins are not substantially parallel can include the amputation of limbs or other regions of the body having substantially curved contoured regions. Wound closure devices fitting over and/or within the wound can require an arcuate shape to be effective to close such wounds. Often different depths within the wound will close at different rates upon the application of negative pressure. It is critical to provide arcuately shaped devices that are effective to close the deeper portions of the wound margins in advance of the shallower portions to avoid the creation of separated wound margin regions that are not visible.


Wound closure devices in accordance with the invention can include one or more device components that are inserted within the wound to facilitate wound closure. A preferred embodiment can employ a double sided anchoring matrix that is inserted in all or a portion of the wound that will attach to both wound margins. The matrix can have apertures extending through the matrix to facilitate wound margin contact through the apertures. One or both sides of the matrix can have tissue anchors to grasp the margin surfaces. Adhesive material can also be used as a tissue anchor material. The matrix can comprise a bio-absorbable material that does not need to be removed from the wound upon wound closure. A further preferred embodiment uses an arcuately shaped closure device in which an outer portion has a larger dimension then an inner portion as the outer portion has a substantially greater length upon insertion into the wound.


In another preferred embodiment for treating an open wound, a common problem involves the drainage and closure of ulcerative conditions. A collapsing structure using negative pressure around therapy and a compression device that is operative to apply a force to the tissue surrounding the wound can also be used to facilitate wound closure. This procedure can also be used with or without sutures to close the wound.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a wound closure device applied to a wound in accordance with various embodiments of the present invention.



FIG. 2 illustrates a wound closure device applied to a wound after initial application of negative pressure in accordance with various embodiments of the present invention.



FIG. 3 illustrates a wound closure device applied to a wound after application of negative pressure in accordance with various embodiments of the present invention.



FIG. 4 illustrates a wound closure device applied to a wound after application of negative pressure in accordance with various embodiments of the present invention.



FIG. 5A illustrates exemplary compression structures and cell shapes in accordance with various aspects and embodiments of the present invention.



FIG. 5B illustrates a single cell shape of the structure shown in FIG. 5A under compression.



FIGS. 5C and 5D illustrate three-dimensional representations of exemplary compression structures in accordance with various embodiments of the present invention.



FIGS. 5E and 5F illustrate top views of collapse of a wall of a cell in a compression structure according to various embodiments of the present invention.



FIG. 5G illustrates a perspective view of collapse of a wall of a cell in a compression structure according to various embodiments of the present invention.



FIG. 6 illustrates a wound closure device including additional structural and drainage elements according to some embodiments of the invention.



FIGS. 7A and 7B illustrate an exemplary cell structure for a compression structure in accordance with various embodiments of the invention.



FIGS. 8A, 8B, and 8C illustrate further cell structure for a compression structure in accordance with various embodiments of the invention.



FIG. 9 illustrates an example anchoring system included in a wound closure device in accordance with various embodiments of the present invention.



FIG. 10 illustrates several grasping features for an anchoring system in accordance with embodiments of the present invention.



FIG. 11 is a schematic diagram of a surgical wound drainage device and related equipment according to some embodiments of the invention.



FIGS. 12A-C show illustrations of embodiments of an adhesion matrix having different types of tissue contact apertures. FIG. 12D is an illustration of an adhesion matrix embodiment possessing tissue anchors on its surface. FIG. 12E shows a cross-sectional view of the adhesion matrix of FIG. 12D.



FIGS. 13A-13C illustrate end views of progressive steps of an exemplary compression structure during compression in accordance with various embodiments of the present invention.



FIGS. 13D-13F illustrate cross-sectional top views corresponding to the end views of FIGS. 13A-13C, respectively.



FIG. 13G illustrates a portion of a compression structure in an extended state in accordance with various embodiments of the present invention.



FIGS. 13H and 13I illustrate portions of the compression structure in extended and collapsed states, respectively, in accordance with various embodiments of the present invention.



FIG. 13J illustrates a portion of a compression structure in a collapsed state in accordance with various embodiments of the present invention.



FIG. 14 illustrates a wound closure device with enhanced force application in accordance with various embodiments of the present invention.



FIG. 15A illustrates a cross-sectional view of a decubitis ulcer injury in a tissue.



FIG. 15B illustrates a wound closure device applied to the decubitus ulcer injury according to various embodiments of the present invention.



FIG. 15C illustrates the wound closure device of FIG. 15B upon application of negative pressure to the device in accordance with various embodiments of the present invention.



FIG. 15D illustrates the wound closure device of FIG. 15C wherein wound margins are nearly approximated in accordance with various embodiments of the present invention.



FIG. 15E illustrates a wound closure device that includes a surgical drain device in accordance with various embodiments of the present invention.



FIGS. 16A-16E illustrate wound closure devices to treat injuries characterized by undermining in accordance with various embodiments of the present invention.



FIG. 17 illustrates a methodology for wound healing and closure in accordance with various embodiments of the present invention.



FIG. 18 illustrates a methodology for wound healing and closure in accordance with various embodiments of the present invention.



FIG. 19 illustrates a methodology for wound healing and closure in accordance with various embodiments of the present invention.



FIG. 20 illustrates a methodology for wound healing and closure in accordance with various embodiments of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention relate to negative pressure wound closure devices, systems, and methods for wounds resulting from amputation or other open wound in which the wound margins undergo rotation to align and close. The embodiments as described herein include a negative pressure source and a compression structure that is placed on the wound to provide directed preferential closure. The compression structure can include a number of cells separated by rigid or semi-rigid membranes that are hinged together at joints. The structure changes conformation during a procedure to facilitate closure of the wound.



FIGS. 1-4 illustrate cross-sections of a wound closure device 100 applied at a body extremity to a wound 150 caused by amputation. The wound closure device 100 can include a compression structure 102, an inlet 105, and flaps 108. The wound closure device 100 can have a dome-shaped geometry in order to extend around the limb in such a way that the peripheral edge 101 of the dome fully surrounds the wound. When a negative pressure is applied to the inlet 105, the compression structure 102 and flaps 108 can apply a force to the wound 150 that is strongest at the deepest point of the wound 150a. The compression structure 102 in combination with the application of negative pressure can exert a force to the wound 150 to facilitate closure of the wound 150 from the deepest internal point 150a as illustrated in FIGS. 1-4 and as described in further detail below. Application of the device can impart a force to spaced-apart wound margins that is operable to move the wound margins to a more closed position.


Although the wound closure device 100 is described as having a dome shape (i.e., a curvature along two axes), it is also contemplated that embodiments of the present invention can have curvature in only one dimension (i.e., a cylindrical geometry). As a non-limiting example, a wound closure device 100 in accordance with the present disclosure can cover a wound on a lateral surface of a bodily limb or extremity such as the thigh. The device can have a range of values of curvature to accommodate wounded extremities as varied as fingers or toes to legs or arms. In some embodiments, the radius of curvature of the device is different from the radius of curvature of the tissue under treatment such that, as a result, the device is at least partially spatially separated from the tissue surface.


The wound 150 can have a width (X) 152 and a depth (Y) 154. In some embodiments, the depth 154 of the wound 150 can be between 0.1 and 1 times the width 152 of the wound 150. Previously available treatments may incompletely treat wounds with such large aspect ratios of depth to width because they typically force the margins of the wound at a shallow portion 150b of the wound to approximate (i.e., come into contact) before the margins of the wound at a deep portion 150a of the wound. In the case where the shallow margins approximate first, the potential arises for seroma formation or infection of the wound below the surface. Embodiments of the present invention can ameliorate this problem by preferentially applying a greater lateral force 110a at the deep portion 150a of the wound 150 than at the shallow portion 150b of the wound as will be described in more detail below.


The compression structure 102 can be situated outside of the wound as shown in FIG. 1 and can have a number of cells 103 separated by walls 107 connected to rigid or semi-rigid membranes 109 that are hinged together at joints. The shape of the cells 103 can be selected based on the shape of the wound 150. Details on the cell shape and composition will be described in greater detail below with reference to FIG. 5. The compression structure 102 can be pre-stressed to exert a compression force on the wound 150 to more quickly bring the wound margins together. Certain elements or cells of the compression structure can have greater compliance to enable interdigitated collapse. In some embodiments, the compression structure 102 can include a circle or spiral format that lays flat in or above the wound to achieve a similar collapsing effect. In various embodiments, the compression structure 102 can be symmetrical or asymmetrical. As the compression structure collapses, the outermost surface of the compression structure 102 can have a larger radius than the innermost surface of the compression structure 102. Note that the walls of adjoining cells extend at different angle due to the arced shape of the device that is needed to extend over the wound. For amputation wounds, the device must have a dome-shaped structure to enclose the wound opening at one end of the limb. In some embodiments, the compression structure 102 is a collapsible structure. The collapsible structure can have a curved contour that extends over at least a portion of tissue adjacent to the wound or wound opening.


The flaps 108 can be attached to the compression structure 102 and can extend to the peripheral edge 101 of the wound closure device 100. In some embodiments, the flaps 108 may include a first section 108a and a second section 108b that are made of different materials or have different properties. In certain embodiments, the first section 108a may be more flexible, stretchable, or elastic than the second section 108b. In some embodiments, the first section 108a, the second section 108b, or both may include anchoring elements 104. The anchoring elements 104 can be used with the flaps 108 on some or all sides of the wound 150 to attach the structure to a wrap 106 that surrounds the limb just proximal to the wound opening. In some embodiments, the second section 108b of the flaps 108 can be made of a stiff material that will not substantially change conformation as the compression structure 102 moves. This stiffness in a section of the flaps 108 can increase the closure force applied to the wound 150.


The wound closure device 100 can be covered with a cover element that can be custom-designed to fit the shape of a particular patient. In some embodiments, the cover element can include a foam or other biocompatible substance. The cover element may include prostheses or can be specially designed to distribute force due to body weight or pressure to prevent adverse wound events such dehiscence.


In some embodiments, a pump or other vacuum source can be used to apply negative pressure to the wound closure device 100. The pump can attach to the inlet 105 of the wound closure device 100. Additional vacuum sources can also be connected through an array of spaced inlets 105 in order to spatially distribute the suction force so that the force exerted on the compression structure 102 can be controlled separately from a fluid suction force. The amount of applied negative pressure can be adjusted depending on the size and shape of the wound. Pressures above 125 mm to as much as 250 mm or more can be used to assist in wound closure. The pressure can be reduced over time as the wound heals and reduces in size and depth. The vacuum source or pump can be further connected in some embodiments with a surgical drain device as described in greater detail below with reference to FIGS. 6, 11 and 12.


In accordance with various embodiments, the inlet(s) 105 can be disposed on an attachment plate 115. The attachment plate 115 may or may not be rigid along certain directions and may be smooth on one or more surfaces. The attachment plate 115 can overlay the compression structure 102 and may also exhibit elastic or stretching properties. The material of the attachment plate 115 can be biocompatible film such as that provided in conjunction with the Renasys® system available from Smith & Nephew. A preferred embodiment can also be used with a gauge as also provided in the Renasys® system. The smooth attachment plate 115 enables the compression structure 102 to contract and expand freely without interference from the underlying tissue, and without damaging the underlying tissue. In a preferred embodiment, the attachment plate 115 includes micropores that allow the passage of fluid through the attachment plate 115 and into the inlet 105 for removal from the wound site. In some embodiments, the attachment plate 115 can contact a wound filling material as described in greater detail below with reference to FIG. 6. In some embodiments, a drain or vacuum tube can extend through the attachment plate and into the wound filling material and/or to the surgical drainage device as described in greater detail below with reference to FIGS. 11-12E.


In some embodiments, the micropores can have different sizes in different regions and/or can have different pore densities in different regions in order to direct different force levels of the vacuum source to different regions of the device 100. Similarly, the compression structure 102 can be engineered with different internal cell sizes and/or cell densities to direct the distribution of forces from the vacuum source to different areas of the device 100.


The wound closure device 100 can be used without any sutures in cases where the skin edges on opposite sides of the wound 150 are sufficiently aligned. Alignment of the skin can be facilitated by surgically trimming the wound margins in advance of closure. In other cases, sutures can be selectively utilized to better align the skin on opposite sides of the wound 150. In various embodiments, the device can be used to treat a range of extremities including legs, arms, fingers, toes, hands and feet. After a period of healing, the device 100 can be removed and optionally replaced with a smaller device.


As described briefly above, the peripheral edge 101 can be designed to impart a greater lateral force 110a than, for example, the lateral force at a point 110b within the wound closure device 100. This gradient of closure force as shown in FIG. 1 can ensure that the maximum depth 150a of the wound 150 experiences a greater force 110a than the shallow depths 150b of the wound 150 to sustain wound margin contact during the application of negative pressure. It is desirable to have the wound margins initiate contact and healing at the deepest portion 150a of the wound 150 and progress from the deepest portion 150a to the shallowest portion 150b such that the skin on opposite sides at the surface of the wound 150 are the final portions of the wound margins to achieve closure. In many cases, the ends of the wound 150 undergo much smaller translation than the center. To accommodate this, the compression structure 102 can be configured with larger cells in the center and smaller cells at the ends of the wound in some embodiments.


In some embodiments, a seal may be included on the flaps 108 or cover element to seal the wound closure device 100 and prevent air from entering or leaving the device while the pressure is changed inside, e.g., by application of negative pressure. The seal can include elastics or adhesives to press a portion of the device 100 such as the peripheral edge 101 against the skin of the patient to produce an airtight seal. In certain embodiments, the seal is included at the peripheral edge 101 of the wound closure device 100.



FIG. 2 shows the device of FIG. 1 shortly after negative pressure has been applied at the inlet 105. The negative pressure can cause the cells of the compression structure 102 to collapse in a preferred direction, e.g., length, width, or height. Due to the difference in forces 110a, 110b at different positions with respect to the wound 150, the wound margins on opposite sides at the deepest part 150a of the wound 150 move into proximity with one another. As the pressure continues to be applied (FIG. 3), the wound margins continue to come into contact from the deepest portion 150a to the shallowest portion 150b of the wound 150. Finally, after the negative pressure has been applied for some time, the wound margins on opposite sides are fully in contact (FIG. 4). The closure of the wound 150 from the deepest point 150a to the shallowest point 150b promotes healing and prevents the development of abscess or other pockets where bacteria can form. The wound closure device 100 can be left attached to the bodily extremity for an extended time period until wound healing is complete.


As shown in FIG. 5A, the compression structure 102 can have a three-dimensional geometry with cells 503 shaped as hexagons having internal membranes that can be arranged symmetrically or asymmetrically. In some embodiments, the cells 503 can include a plurality of polygonal shapes, irregular shapes, or both including, but not limited to, triangles, squares, parallelograms, pentagons, or any n-gon. In one embodiment, the cells 503 of the compression structure 102 can be a portion of a truncated icosahedron (i.e., a soccer ball). The cells 503 can be made of a pliable material.


In some embodiments, the interior of each cell 503 contains internal membranes or walls 505 to enhance structural stiffness in one or more directions. The internal membranes or walls 505 can be connected by hinged elements 506. As a result of this enhanced stiffness, the cells 503 can preferentially collapse along a specific dimension (e.g., length, width, or height) as shown in FIG. 5B. In accordance with various embodiments, a cell 503 can have a sufficient rigidity due to the presence of internal membranes 505 that the cell does not expand in a direction perpendicular to the preferred axis of compression or collapse. In some embodiments, this is accomplished through the use of single- or double-hinging. The internal membranes 505 of adjoining cells 503 can be oriented at different angles to accommodate the rotational component of the tissue movement during a wound closure procedure. These features can apply to any wound shape in which the wound margins undergo a more complex movement (compared to the substantially one-dimensional lateral movement of the abdominal walls associated with abdominal wound closure). Materials including structural elements, foam, tissue anchors, and operation of closure devices as described in International Patent Application PCT/US2013/050698, filed Jul. 16, 2013, and U.S. patent application Ser. No. 13/365,615, filed Feb. 3, 2012, and also U.S. application Ser. No. 13/942,493 filed on Jul. 15, 2013, the entire contents of the above-referenced applications being incorporated herein by reference, can be used in conjunction with the devices and methods set forth herein.



FIG. 5C illustrates a three-dimensional view of a wound closure device 100 in accordance with embodiments of the present invention. The dome-shaped device can be broken up into cells 503 having one or more shapes as discussed above. In the embodiment of FIG. 5C, the cell shape is triangular and the triangles tessellate to form hexagonal structures. FIG. 5D illustrates a portion of a structure such as the dome-shaped device of FIG. 5C. In some embodiments, the device can include individual cells 503 that are substantially flat and are joined to one another through the use of hinges 508. The hinges 508 can allow relative movement and re-orientation of adjacent cells 503 to better conform the wound closure device 100 to a wound 150.



FIGS. 5E-5G are insets illustrating a portion of the wound closure device 100 indicated in FIG. 5A. In FIG. 5E, the walls between cells 503 are in their typical extended form. When negative pressure is applied in the device, the cells will contract in size as the wound margins begin to approximate as described above with reference to FIGS. 1-4. In some embodiments, the walls between cells 503 can include fold points at which the walls break or buckle to allow the cells 503 to contract in size as pressure is applied. The resulting walls upon folding are illustrated in top view in FIG. 5F and in perspective in FIG. 5G. In some embodiments, a network of cells 503 is rigid enough to compress and provide force to pull attached flaps 108. The flaps 108, in turn, can generate a force on attached tissue that surrounds the wound to provide a force to close the deep portion of the wound before the shallow portion.



FIG. 6 illustrates a wound treatment system 600 including a wound treatment device 100 that works in cooperation with additional structural and drainage features to accelerate wound healing in accordance with various embodiments of the present invention. The system 600 can include a surgical drain device 660 that attaches to the exposed wound surfaces in proximity to the deepest portion 150a of the wound 150. The surgical drain device 660 can include features and methods described in U.S. patent application Ser. No. 13/675,736, filed Nov. 13, 2012, International Application PCT/US2012/033608 filed on Apr. 13, 2012, and also in U.S. application Ser. No. 14/111,977 filed on Oct. 15, 2013, the entire contents of the above applications being incorporated herein by reference. The system 600 can also include a wound filler material 670 such as collapsing structure with foam elements and optionally including tissue anchors that attach to the wound margins that is placed in proximity to the shallow portion 150b of the wound 150.


The surgical drain device 660 can include apertures to allow wound margins on opposite sides of the drain device 660 to come into contact. In some embodiments, the surgical drain device 660 has a plurality of removable drainage tubes that can be withdrawn from the device. In various embodiments, the surgical drain device 660 is made of a bio-absorbable material such that the body of the device can be left in the wound 150 without needing to be removed. The material 670 can be attached to the tube elements 675 such that removal of material 670 from the wound 150 will extract the tubes 675 from drain device 660. The surgical drain device is described in greater detail below with reference to FIGS. 11-12E. In some embodiments, the tubes 675 can be similar to the plurality of drain tubes 30 as described below.


One embodiment of a cell framework for a compression structure 102 according to the invention is shown in FIGS. 7A and 7B. As discussed above, the compression structure 102 can have a curvature in one dimension (i.e., substantially cylindrical) or in two dimensions (i.e., substantially spherical or dome-like). The cells 503 can include a first set of x-y stabilizer elements 808a and a second set of x-y stabilizer elements 808b that are connected by a plurality of z-axis stabilizer elements 810. During collapse of the compression structure 102, the respective x-y stabilizer elements 808a, 808b are collapsible in the x-y directions, but the z-axis stabilizer elements 810 inhibit collapse in the z-direction. In preferred embodiments, the stabilizer elements can articulate with respect to one another during collapse. The joints 809 in the structure can be hinged or have a reduced thickness to accommodate the flexing of the system. Note that the first, upper set of stabilizer elements 808a is longer than the second, lower set of stabilizer elements 808b. The flexures between the joints may also flex to accommodate the desired compression along a first, or lateral, axis 117. Some expansion can occur along the second, or longitudinal, axis 119 as the device compresses. The material of the compression structure 102 can have a shape memory characteristic that, in combination with the force due to negative pressure, defines the force level applied to the tissue. In some embodiments, the stabilizer elements 808 can include a plurality of stabilizing ribs, flexures or rods, made from a suitably rigid or semi-rigid material, such as plastic. The spacing between the elements in the “open” state can be in a range of 1-2 cm, for example. In accordance with various embodiments, the first set of x-y stabilizer elements 808a disposed on the outermost surface of the compression structure 102 can have longer segment lengths than the second set of x-y stabilizer elements 808b disposed on the innermost surface of the compression structure 102. In different embodiments, the first set of x-y stabilizer elements 808a disposed on the outermost surface of the compression structure 102 can have a larger or equal radius of curvature than the second set of x-y stabilizer elements 808b disposed on the innermost surface of the compression structure 102.


In another embodiment, shown in FIGS. 8A and 8B, the cells of the compression structure 102 can include truss stabilizers 812 to inhibit tilting of the structure 102 during collapse. The truss stabilizers 812 keep the upper 808a and lower 808b x-y stabilizers aligned with one another as the compression structure 102 collapses. In some embodiments, the truss stabilizers 812 can be rigid in certain directions and relatively less rigid in other directions (for example, the truss stabilizer can be bowed) to promote collapse in certain directions. FIG. 8C illustrates an alternative embodiment having truss stabilizers 812 in an “x”-shaped pattern.


The cells 503 in certain embodiments can be made, in whole or in part, from a shape memory material. Various shape memory materials can be used which return from a deformed state (temporary shape) to their original (permanent) shape. This change in shape can be induced by an external stimulus or trigger. In one embodiment, the original or “permanent” shape of the wound closure device is the “collapsed” configuration. When the wound closure device is initially applied at the wound, the device can be deformed in a temporary expanded state. The device can preferentially revert to its original or “collapsed” state or, alternatively, cause the device to first expand to engage the tissue. The “collapse” force of the shape memory structure can be in addition to or an alternative to the vacuum force induced by the negative pressure source. In certain embodiments, the application of a negative pressure to the wound closure device can cause the device to revert to its original state.



FIG. 9 illustrates an enlarged view of a preferred embodiment of a tissue anchor system 400 in accordance with some aspects of the invention. One side of the flaps 108 can have a first group of anchor elements 404 that are adapted to grasp the wrap 106 and/or the tissue. The first anchor elements 404 can be shaped to grasp the wrap 106 such as with a distal hooked shape 406. As the flaps 108 attach to the wrap 106 with a certain grasping strength in order to sufficiently affix the wound closure device to the bodily extremity, a specified force level F must be applied to remove the anchor elements 404 from the wrap 106 that exceeds the pulling force being applied to the device 100.


In some embodiments, the flaps 108 can attach at least in part to the tissue of a patient including dermal tissue. As the tissue to be grasped by the flaps 108 has different structural characteristics then the wrap 106, a second group of anchor elements can be adapted to grasp tissue and can have a different shape and grasping force then the first anchor elements 404. As discussed in greater detail below, barbs can have bilateral prongs that tend to collapse upon insertion in tissue and yet expand when pulled in an opposite direction such that a certain pulling force can be applied to tissue as the compression structure 102 collapses. However, the prongs or cone shape anchor element can have a release force such that the barbs can be manually pulled from the tissue without causing injury. In some embodiments, the flaps 108 attach to both tissue and the wrap 106.


The characteristics of the anchors, and their resulting force profiles, can vary by a number of parameters, such as the length of the anchor, the shape of the anchor, the structure of grasping features, the material(s) used for the anchor, the relative flexibility/rigidity of the anchors, and the spacing/density of the anchors. FIG. 10 illustrates three examples of different types of grasping features, including a barbed configuration 605, a staggered hook configuration 606, and a staggered barbed configuration 607. The anchoring process can be augmented by the application of a seal as described above. The force profile can also be varied by controlling the vacuum force distribution in the compression structure 102, such as by varying the cell size and/or cell density of the compression structure 102.



FIG. 11 schematically depicts a surgical drain device 660 and accompanying support equipment for drainage of at least a portion of a wound. The surgical drain device 660 can have a plurality of drain tubes 30 attached to an adhesion matrix 25 and configured so as to drain the full extent of the portion of the wound. The drain tubes 30 can be connected at their proximal ends to a manifold 40 that can in turn be connected through vacuum tubing 50 to a vacuum pump 130 or other vacuum source. Fluid 125 drained from the wound can be optionally accumulated in fluid trap 120. In some embodiments, the vacuum tube 50 and manifold 40 connect to a valve or port in the wound filler material 670. In this embodiment, removal of the wound filler material 670 (i.e., at the end of a wound closure operation) can release the manifold 40 and attached plurality of drain tubes 30 from the surgical drain device 660. The adhesion matrix 25 can be made of a bioabsorbable material and may be left in the body once the drain tubes 30 have been removed. Vacuum pump or other vacuum source 130 can include one or more electronic devices, such as a microprocessor with memory and software, to monitor the vacuum level, pneumatic resistance, and/or fluid removal amount or rate. The electronic device(s) also can be used to control the operation of the system over time according to user-defined parameters, according to a preset program, or in response to data collected on vacuum, resistance, and/or fluid removal.


The number of drain tubes in the surgical drain device 660 can vary depending upon the needs of the device, including the amount of fluid to be drained and the size of the wound and shape of the device. Typically, the device will contain from 2 to about 20 drain tubes. In a preferred embodiment, the device contains preferably at least 3 tubes, and for larger areas from about 5 to about 12 tubes.


The drain tubes 30 can be fabricated from any biocompatible thermoplastic or thermoset material. Examples include surgical grade silicone rubber, polyurethane, polyamide, polyimide, PEEK (polyether ether ketone), polycarbonate, PMMA (polymethylmethacrylate), and polyvinylchloride. The drain tubes 30 are intended to be removed after fluid build-up has reduced to a level that is stable without drainage. However, in an alternative embodiment, the drain tubes 30 can be made of a biodegradable material and can be left in place. The drain tubes 30 can be flexible so as to conform to the tissues surrounding the device and to accommodate movement of the patient without causing discomfort. The drain tubes can be open ended or close ended. In a preferred embodiment, the drain tubes are close ended and possess apertures or holes along their length for the uptake of fluid.



FIGS. 12A-E show several embodiments of the adhesion matrix 25. A portion of the adhesion matrix 25 between two neighboring drain tubes 30 and drain channels 35 is shown. The embodiment shown in FIG. 12A has a regular arrangement of rectangular apertures 27 to allow tissue contact through the device. This tissue contact enables a faster healing rate at the apertures 27. Circular apertures are shown in FIG. 12B. The embodiment of FIG. 12C includes apertures 27 that are formed into lateral channels. Fluid flows laterally through these channels toward openings 36 in the drain tube channels 35, drawn by the reduced pressure in the drain tubes 30. As shown in FIGS. 12D and 12E, the surfaces of the adhesion matrix, including the drain channels, can be endowed with an array of hooks or barbs to promote anchoring of the device to adjacent tissues. In the embodiment shown in FIG. 12E, the hooks on the upper side 28 are longer than the hooks on the lower side 29. This arrangement can be used where the tissues on either side of the device are of different density. For example, longer hooks such as about 1.5 to about 3 mm in length are preferred for less dense tissue, such as subcutaneous fat tissue, whereas shorter hooks such as about 0.5 to about 1.5 mm in length are preferred for denser tissues such as fascia and muscle.


The adhesion matrix 25, including any drain tube channels 35 and hooks or barbs, can be fabricated from a biodegradable polymer material, as these structures are intended to remain in place in the patient's body after removal of the drain tubes 30, so as not to disrupt the healing process. Examples of suitable biodegradable or resorbable materials include Vicryl (polyglycolic acid), Monocryl (glycolic acid-ε-caprolactone copolymer), PDS (polydioxanone, PDO), PLA (polylactic acid, polylactide), PLLA (poly-L-lactic acid), PDLA (poly-D-lactic acid), PGA (polyglycolic acid, polyglycolide), PLGA (poly(lactic-co-glycolic acid)), PHB (polyhydroxybutyrate), and PCL (polycaprolactone). In a preferred embodiment, the adhesion matrix 25, including any drain tube channels 35, is formed of an open network of polymer chains that has sufficient porosity to allow infiltration by cells and fluid flow across the material. Cellular infiltration can promote tissue adhesion and the biodegradation of the polymer after the wound has healed. In some embodiments, the adhesion matrix 25 including any drain tube channels 35 is permeable to seroma fluid but not permeable to cells. In other embodiments, the adhesion matrix 25, including any drain tube channels 35, is permeable to fluid and electrolytes but is impermeable to proteins. The permeability properties of the matrix polymer material that makes up the basic substrate of the adhesion matrix 25 can be the same or different compared to the material that makes up the drain tube channels 35. In a preferred embodiment, the polymer chains, or fibers composed of polymer chains, of the adhesion matrix 25 are aligned along an axis substantially perpendicular to the axes of the nearest drain tubes 30. This alignment pattern promotes the flow of fluid through or along the surface of the adhesion matrix 25 towards the drain tubes.


The adhesion matrix 25, and thus the overall drain device 660, can have any form suitable for insertion into the wound or seroma where it is to be inserted. Generally, the form is that of a thin sheet or flexible planar mesh having an essentially rectangular shape. However, the shape can be rounded, circular, elliptical, oval, or irregular. Preferably the corners are rounded so as to minimize mechanical irritation of surrounding tissues. The size of the device is also determined by the particular use and anatomy of the patient. For example, the adhesion matrix can have an overall width and length in the range from about 2 cm to 25 cm, such as about 10 cm×12 cm or about 20 cm×25 cm. The thickness of the adhesion matrix 25 can be from about 0.5 mm to about 1 cm; where the sheet of material is preferably less than 5 mm in thickness and preferably the adhesion matrix 25 is about 1-2 mm thick. The thickness of the entire drain device 660, including the sheet of the adhesion matrix 25, drain tubes 30, and any hooks or glue pads is about 5 mm or less, 10 mm or less, or about 5-10 mm.


The adhesion matrix 25 can be coated with an adhesive material such as surgical glue either in addition to or instead of using hook or barb structures that stabilize tissue layers on either side of the drain device. Any type of surgical adhesive suitable for use within the body can be used, including polyethylene glycol polymers, adhesive proteins, gelatin-thrombin mixtures, albumin-glutaraldehyde, and fibrin-based sealants. Cyanoacrylates are to be avoided, as they cause inflammation if used internally. An adhesive coating can be placed on one or both surfaces of the adhesion matrix 25. Adhesive coatings can be applied to the device prior to its placement in a patient, i.e., as part of the device fabrication process. An adhesive coating can cover all or a portion of a surface of the device 660. A surgical adhesive can be used in the form of a fibrous mat or pad that is soaked or coated with an adhesive composition. The mat or pad is preferably fabricated from a biodegradable polymer, such as the type used to prepare the adhesion matrix 25. One or more layers of adhesive material can be placed between the device and surrounding tissue at the time of placement in the patient.


When the wound closure device 100 containing the compression structure 102 is applied to a wound 150 and negative pressure is applied, the wound margins will begin to approximate beginning with the deep portion of the wound 150a. As the wound margins rotate towards one another, the compression structure 102 must also compress along the lateral direction 117. Compression or collapse of the compression structure 102 can be achieved by several methods. FIGS. 13A-13F illustrate an embodiment of a portion of a compression structure 102 as it collapses in size. The compression structure 102 is depicted in an unstressed, expanded state in FIGS. 13A (end view) and 13D (top cross-sectional view). In some embodiments, the expanded state may be the natural resting state of a compression structure 102. In the expanded state, the rigid or semi-rigid membranes 109 can be substantially perpendicular to the cell walls 107. In FIGS. 13B and 13E, the portion of the compression structure 102 is depicted in an intermediate state of collapse. In accordance with various embodiments, the membranes 109 can be joined to the walls 107 using hinges or any other attachment method that allows the membranes 109 to rotate or pivot with respect to the walls 107. The compression structure 102 is depicted in the collapsed state in FIGS. 13C and 13F. In some embodiments, the walls 107 of the compression structure 102 re-orient from a fan- or V-shape as seen in an end view to being substantially parallel in the compressed state. This rotation of the walls 107 mirrors the rotation of the wound margins as they begin to approximate during closure and healing of the wound 150.



FIG. 13G illustrates a portion of a compression structure 102 including rigid or semi-rigid membranes 109 and walls 107 in accordance with various embodiments of the present invention. In accordance with various embodiments, the membranes 109 can include multiple interlocking sections such as an inner sliding section 109b and an outer sliding section 109a as shown in FIGS. 13H and 13I. In some embodiments, the inner sliding section 109b can be configured to fit partially or wholly within an adjacent outer sliding section 109a. In a first, extended state as shown in FIG. 13H, the inner sliding section 109b is withdrawn from the outer sliding section 109a to provide the maximum possible extension. As the compression structure 102 compresses, the inner sliding sections 109b will gradually slide into the body of the outer sliding sections 109a as shown in FIG. 13I. In some embodiments, the inner sliding section 109b can slide within an outer sliding section 109a until an adjoining wall 107 prevents further sliding. The resulting reduction in the total length of the membranes 109 is depicted in FIG. 13J.



FIG. 14 illustrates a cross-section of a wound closure device 100 applied at a body extremity to a wound 150 caused by amputation. The wound closure device 100 can include a collapsible structure 102, an inlet 105, and a drape 118. The wound closure device 100 can have a dome-shaped geometry in order to extend around the limb in such a way that the peripheral edge of the dome fully surrounds the wound. When a negative pressure is applied to the inlet 105, the collapsible structure 102 and drape 118 can apply a force to the wound 150 that is strongest at the deepest point of the wound 150a. The collapsible structure 102 in combination with the application of negative pressure can exert a force on the wound 150 to facilitate closure of the wound 150 beginning with the deep portion of the wound 150a.


Although the wound closure device 100 is described as having a dome shape (i.e., a curvature along two axes), it is also contemplated that embodiments of the present invention can have curvature in only one dimension (i.e., a cylindrical geometry). As a non-limiting example, a wound closure device 100 in accordance with the present disclosure can cover a wound on a lateral surface of a bodily limb or extremity such as the thigh. The device can have a range of values of curvature to accommodate wounded extremities as varied as fingers or toes to legs or arms. In some embodiments, the radius of curvature 116 of a portion of the device (RC2) is different from the radius of curvature 156 of the tissue (RC1) under treatment such that, as a result, the device is at least partially spatially separated from the tissue surface.


The wound 150 can have a width (X) 152 and a depth (Y) 154. In some embodiments, the depth 154 of the wound 150 can be between 0.1 and 1 times the width 152 of the wound 150. Previously available treatments may incompletely treat wounds with such large aspect ratios of depth to width because they typically force the margins of the wound at a shallow portion 150b of the wound to approximate (i.e., come into contact) before the margins of the wound at a deep portion 150a of the wound. In the case where the shallow margins approximate first, the potential arises for seroma formation or infection of the wound below the surface. Embodiments of the present invention can ameliorate this problem by preferentially applying a greater lateral force 110a at the deep portion 150a of the wound 150 than at the shallow portion 150b of the wound as will be described in more detail below. In accordance with various embodiments, a portion 114 of the wound closure device 100 can be positioned over tissue adjacent to the wound 150. In some embodiments, the length of the portion 114 adjacent to the wound 150 can be 0.4 to 0.8 times the depth 154 of the wound 150.


The collapsible structure 102 can be situated outside of the wound as shown in FIG. 1 and can have a number of cells 103 separated by walls 107 connected to rigid or semi-rigid membranes 109 that are hinged together at joints. The shape of the cells 103 can be selected based on the shape of the wound 150. Details on the cell shape and composition will be described in greater detail below with reference to FIG. 5. The collapsible structure 102 can be pre-stressed to exert a compression force on the wound 150 to more quickly bring the wound margins together. Certain elements or cells of the collapsible structure can have greater compliance to enable interdigitated collapse. In some embodiments, the collapsible structure 102 can include a circle or spiral format that lays flat in or above the wound to achieve a similar collapsing effect. In various embodiments, the collapsible structure 102 can be symmetrical or asymmetrical. As the collapsible structure collapses, the outermost surface of the collapsible structure 102 can have a larger radius than the innermost surface of the collapsible structure 102. Note that the walls of adjoining cells extend at different angles due to the arced shape of the device that is needed to extend over the wound. For amputation wounds, the device must have a dome-shaped structure to enclose the wound opening at one end of the limb. The collapsible structure can have a curved contour that extends over at least a portion of tissue adjacent to the wound or wound opening. As described above with reference to FIGS. 13A-J, the collapsible structure can include articulating elements that undergo rotational movement during closure of the wound margins within a wound such as an amputation wound. In some embodiments, the articulating elements can rotate at joints such that the collapsible structure collapses along a curved path above the wound opening.


The collapsible structure 102 can include rigid or semi-rigid membranes 109 connecting walls 107 between cells 103. The lower set of membranes 109 can form a surface having a smaller radius of curvature 116 than the radius of curvature 156 of the surface of the tissue proximate to the wound. In some embodiments, the smaller radius of curvature is enforced by stiffened or firm elements within the collapsible structure 102. The difference in the radius of curvature 116 of the collapsible structure 102 relative to the radius of curvature of the tissue surface can impart additional force at the lateral ends of the collapsible structure 102. In some embodiments, the firmness or stiffness of the radius of curvature of the collapsible structure 102 can help allow the structure to resist buckling when a negative pressure is applied at the port 105. In some embodiments, the collapsible structure 102 can include a lateral portion that can apply an inward force to the deep portion 150a of the wound 150 to cause the deep portion 150a to close before the shallow portion 150b. In accordance with various embodiments, the collapsible structure 102 can contact the portion of the tissue adjacent to the wound opening and can include a stiff edge.


The drape 118 can provide a leak-free seal between the wound closure device 100 and the tissue surface. In some embodiments, the drape 118 can be made from materials including plastics or tapes and further including biocompatible materials. In some embodiments, the drape 118 can include adhesives or surgical glues as described above with reference to the adhesion matrix 25. The drape 118 can improve sterility of the wound 150 during healing by preventing ingress of dirt or bacteria. In some embodiments, the drape 118 can affix a lateral portion of the collapsible structure 102 to tissue surrounding at least the deep portion 150a of the wound 150.


The wound closure device 100 can be covered with a cover element that can be custom-designed to fit the shape of a particular patient. In some embodiments, the cover element can include a foam or other biocompatible substance. The cover element may include prostheses or can be specially designed to distribute force due to body weight or pressure to prevent adverse wound events such dehiscence.


In some embodiments, a pump or other vacuum source can be used to apply negative pressure to the wound closure device 100. The pump can attach to the inlet 105 of the wound closure device 100. Additional vacuum sources can also be connected through an array of spaced inlets 105 in order to spatially distribute the suction force so that the force exerted on the collapsible structure 102 can be controlled separately from a fluid suction source. The amount of applied negative pressure can be adjusted depending on the size and shape of the wound. Pressures above 125 mm to as much as 250 mm or more can be used to assist in wound closure. The pressure can be reduced over time as the wound heals and reduces in size and depth. The vacuum source or pump can be further connected in some embodiments with a surgical drain device as described in greater detail above with reference to FIGS. 6, 11 and 12.


In accordance with various embodiments, the inlet(s) 105 can be disposed on an attachment plate 115. The attachment plate 115 may or may not be rigid along certain directions and may be smooth on one or more surfaces. The attachment plate 115 can overlay the collapsible structure 102 and may also exhibit elastic or stretching properties. The material of the attachment plate 115 can be biocompatible film such as that provided in conjunction with the Renasys® system available from Smith & Nephew. A preferred embodiment can also be used with a gauge as also provided in the Renasys® system. The smooth attachment plate 115 enables the collapsible structure 102 to contract and expand freely without interference from the underlying tissue, and without damaging the underlying tissue. In a preferred embodiment, the attachment plate 115 includes micropores that allow the passage of fluid through the attachment plate 115 and into the inlet 105 for removal from the wound site. In some embodiments, the attachment plate 115 can contact a wound filling material as described in greater detail above with reference to FIG. 6. In some embodiments, a drain or vacuum tube can extend through the attachment plate and into the wound filling material and/or to the surgical drainage device as described in greater detail above with reference to FIGS. 11-12E.


In some embodiments, the micropores can have different sizes in different regions and/or can have different pore densities in different regions in order to direct different force levels of the vacuum source to different regions of the device 100. Similarly, the collapsible structure 102 can be engineered with different internal cell sizes and/or cell densities to direct the distribution of forces from the vacuum source to different areas of the device 100.


The wound closure device 100 can be used without any sutures in cases where the skin edges on opposite sides of the wound 150 are sufficiently aligned. Alignment of the skin can be facilitated by surgically trimming the wound margins in advance of closure. In other cases, sutures can be selectively utilized to better align the skin on opposite sides of the wound 150. In various embodiments, the device can be used to treat a range of extremities including legs, arms, fingers, toes, hands and feet. After a period of healing, the device 100 can be removed and optionally replaced with a smaller device.


In many cases, the ends of the wound 150 undergo much smaller translation then the center. To accommodate this, the collapsible structure 102 can be configured with larger cells in the center and smaller cells at the ends of the wound in some embodiments.


The wound closure device 100 can also include a compression element 121 such as a clamp to increase the amount of force applied at the deep portion 150a of the wound. In some embodiments, the compression element 121 can include only discrete points of contact around the wound such as with a surgical clamp or distractor or can surround the wound at all sides such as with an elastic band. In some embodiments, the compression element 121 can include a tacky or rubberized surface or an adhesive to improve contact with the tissue and prevent relative movement of the compression element 121 over the tissue surface during wound closure.


Some types of incisions and wounds are characterized by a greater area at the base (i.e., the deepest portion) of the wound than at the skin surface. FIG. 15A illustrates a cross-section of such a wound, which may be a pressure ulcer, a sacral decubitus ulcer, or an ischial decubitus ulcer in some embodiments. Such a wound could also be generated by drainage of a fluid-filled cavity such as an abscess or seroma. The inset wound 1610 is characterized by overhanging skin flaps 1604 that are undermined by a portion of the wound volume 1612. The undermined portion of the wound volume 1612 may create an especially difficult barrier to healing because of the risk of seroma or bacterial infection should the surface portion of the wound close before the margins in the hidden portion are properly closed. Due to the location and orientation of some ulcers of this type, the inset wound 1610 can lie in a concavity in the tissue 1600 with respect to high points 1602 surrounding the inset wound 1610. As a result, typical surgical dressings applied to the wound cannot apply sufficient pressure on the wound surface to effect proper drainage or to encourage the margins of the inset wound 1610 at the surface and in the undermined portion 1612 to properly approximate.



FIG. 15B illustrates a wound closure device 1000 that can be applied to an inset wound 1610 in accordance with various embodiments of the present invention. The wound closure device 1000 can include a compression element such as a bladder 1010, a drape 1050, an inlet 105, and a porous stem 1020. The wound closure device 1000 can be placed within the inset wound 1610. When negative pressure is applied at the inlet 105 as shown in FIG. 15C, the device 1000 can conform to the surface of the tissue 1600 and provide compressive force to the skin flaps 1604 to create apposition of the wound tissue under the skin flips and at the base of the wound. In some embodiments, additional compressive force can be generated by inflating or filling the compression element. By forcing the wound margins into apposition, the wound margins can approximate more quickly and can close off the undermined portion 1612 before approximation and closure occurs at the skin surface. An exemplary application of a wound closure device 1000 to bring the margins in the undermined portion into opposition is shown in FIG. 15D.



FIG. 15E illustrates a cross-sectional view of a wound closure device 1000 that includes a surgical drain device 660 in accordance with various embodiments of the present invention. The stem 1020 of the wound closure device 1000 can be in contact with at least a portion of the surgical drain device 660. As described above with reference to FIGS. 6 and 9-12E, the surgical drain device 660 can include apertures 27 to allow wound margins on opposite sides of the drain device to come into contact through the device. In some embodiments, the surgical drain device 660 can include drain tubes 30 to carry fluid from the wound 1610 to the stem 1020. In some embodiments, the drain tubes 30 can be attached to the stem 1020 or another element of the wound closure device 1000 and can be removed from the surgical drain device 660 when the wound closure device 1000 is removed from the wound 1610. In some embodiments, the surgical drain device 660 can include drain channels that are coupled to the stem 1020 to allow fluid to be drawn to the stem 1020 and out of the wound cavity.


In some embodiments, the surgical drain device 660 can include tissue anchors 404 as described previously. The tissue anchors 404 can attach to the wound margins on the underside of the skin flaps 1604 and at the base of the wound. In some embodiments, the tissue anchors 404 can improve approximation of wound margins that, due to tissue inelasticity or wound geometry, simply cannot stretch enough to meet under pressure from the bladder 1010.


In accordance with various embodiments, the stem 1020 can be a collapsible element that can collapse in both the horizontal and vertical directions (i.e., the depth and lateral directions according to the wound geometry). As negative pressure is applied, the stem 1020 can collapse in the vertical direction to allow wound margins in the undermined portion 1612 of the wound 1610 to approximate. The stem 1020 can also collapse in the horizontal direction to allow the wound margins in the surface portion of the wound (i.e., the skin flaps 1604) to approximate. In some embodiments, the stem 1020 can contain a collapsible structure as described above with reference to previous embodiments.



FIG. 16A shows a perspective view of a wound closure device 1000 in accordance with various embodiments of the present invention. In accordance with various embodiments, the device 1000 can include a compression element such as a bladder 1010, a porous stem 1020, a port 1012, and a pressure sensor 1014.


The bladder 1010 of the wound closure device 1000 can be made of any suitable material including, but not limited to, plastics, rubbers, or fabrics. The bladder 1010 can have a level of malleability and compliance such that it can mold to fill irregularities across a tissue surface. In some embodiments, the bladder 1010 may be filled with air or other gases, liquids such as saline, or colloidal materials such as gels or foams. In some embodiments, the bladder can be inflated by introducing filler material through the port 1012. As a non-limiting example, the bladder 1010 can be filled by a pump such as a hand- or battery-operated portable pump. One skilled in the art will appreciate that other methods of filling the bladder 1010 are also contemplated as being within the scope of the present invention including in-house and other stationary pressure sources, mouth-blowing, and integrated pumps or micro-pumps mounted within or on the bladder 1010. In some embodiments, the pressure within the bladder 1010 can be adjusted by the patient. In some embodiments, the bladder 1010 can include an integrated or detachable pressure gauge to measure the level of pressure within the bladder 1010.


The porous stem 1020 can be made of any suitable material including, but not limited to, biocompatible foam or gauze. In accordance with various embodiments, the porous stem 1020 can compress as negative pressure is applied as shown in the transformation of the stem between FIGS. 15B and 15C. The porosity of the stem 1020 can allow fluids to be drawn up within or through the stem 1020 to facilitate drainage of the wound 1610.


As with most wounds, an inset wound 1610 may be sensitive to the applied pressure. If the applied pressure is too great, adverse healing may ensue due to restricted blood flow or other causes. The pressure sensor 1014 can detect the magnitude of the applied force on the tissue at the surface of the skin. In some embodiments, the pressure sensor 1014 may be connected to the inlet 1012 to relieve overpressure within the bladder 1010 when the level of pressure on the tissue surface is too high.


When applied to a wound 1610, the wound closure device 1000 can include a drape 1050 to create a leak-free seal between the wound closure device 1000 and the surface of the tissue 1600. In some embodiments, the drape 1050 can be made from materials including plastics or tapes and further including biocompatible materials. In some embodiments, the drape 1050 can include adhesives or surgical glues as described above. The drape 1050 can improve sterility of the wound 1610 during healing by preventing ingress of dirt or bacteria. In some embodiments, the drape 1610 can extend from the wound 1610 to beyond at least the high points 1602 of the surrounding tissue surface. In some embodiments, the drape 1050 includes an inlet 105 through which negative pressure may be applied to the wound closure device 1000.



FIG. 16B illustrates a cross-sectional view of a wound closure device 1000 having a shell 1015 in accordance with various embodiments of the present disclosure. In various embodiments, the shell 1015 can be a separate external element attached to the bladder 1010 or can be integrated within the bladder 1010. The shell 1015 can be made of unyielding, firm, or rigid materials such that it holds its shape and is not pliable like the remainder of the bladder 1010. When negative pressure is applied to the device 1000, the drape 1050 will pull taut against the shell and apply pressure downward. Because of the rigidity of the shell 1015, the applied pressure will be primarily directed into the tissue 1600 (rather than into reshaping the bladder 1010) and thereby increase the overall force that can be applied to the skin flaps 1604 for the same level of negative pressure as compared to a device 1000 having no shell 1015.



FIG. 16C illustrates a cross-sectional view of a wound closure device 1000 with a drain tube 1024 that passes through the bladder 1010. An alternative location of a drain tube 1026 is shown in FIG. 16D. In this embodiment, the drain tube 1026 passes below the bladder 1010 and beyond the bladder's periphery. In some embodiments, a pump can be connected to the drain tube 1024, 1026 to extract accumulated fluids via the porous stem 1020. In some embodiments, the drain tubes 1024, 1026 can be connected with the inlet 1012 to allow a single source of negative pressure to extract accumulated fluids and to create negative pressure within the wound closure device 1000.



FIG. 16E illustrates an embodiment of a modular bladder 1010 in accordance with various embodiments of the present invention. The modular bladder 1010 may be made of individual sections 1011 separated by seams 1017. In some embodiments, the modular bladder 1010 may be cut or torn along the seams to remove sections 1011 until the desired bladder size is achieved. In accordance with various embodiments, each bladder section 1011 may be individually inflatable or fillable to provide different levels of pressure at different points on the bladder 1010. Although the modular bladder 1010 is depicted as having a grid of square sections, it is also contemplated that the modular bladder could include concentric ring sections, tessellating sections having other shapes than rectangles, or any other suitable shape as dictated by application-specific needs. In some embodiments, the seams 1017 can be self-sealing or self-healing such that each section 1011 becomes or remains pressurized or filled upon cutting or tearing at the seams 1017.



FIG. 17 illustrates an exemplary methodology 1200 for wound healing and closure in accordance with various embodiments of the present invention. In step 1202, an open wound at a body region having a depth including a deep portion and a shallow portion is surgically prepared for negative pressure wound therapy. For example, the open wound can be an amputation wound in a body region such as an amputated limb. A wound closure device is configured that includes a collapsible compression structure for the wound opening (step 1204). The configured wound closure device has a size and shape that conforms to the wound opening. The wound closure device is placed over the open wound (step 1206). Negative pressure is applied at a port or inlet to cause the compression structure to at least partly collapse (step 1208). The collapse of the compression structure causes the deep portion of the wound margins to close before the shallow portion. The wound closure device can optionally be removed and a second wound closure device can be applied to the wound (step 1210). The wound closure device can be removed, and the wound closure can be completed with or without sutures (step 1212).



FIG. 18 illustrates an exemplary methodology 1400 for wound healing and closure in accordance with various embodiments of the present invention. A wound in a tissue that has a depth including a deep portion and a shallow portion is surgically prepared for negative pressure wound closure therapy (step 1402). A wound closure device including a collapsible structure, flaps, and a port or inlet is configured (step 1404). The collapsible structure has a radius of curvature. Optionally, a surgical drain device is placed into the wound. The wound closure device is placed over the wound in the tissue (step 1406). A surface of the tissue surrounding the sound defines a radius of curvature that is greater than the radius of curvature of the collapsible structure. The tissue is optionally compressed on opposite sides of the wound while the wound closure device is attached to tissue surfaces surrounding the wound (step 1408). Negative pressure is applied at the inlet to cause the collapsible structure to at least partly collapse (step 1410). The collapse of the collapsible structure causes the deep portion of the wound to close before the shallow portion. The wound is drained of fluids during movement of the wound margins (step 1412). The wound closure device is removed from the wound, and the wound is closed with or without sutures (step 1414).



FIG. 19 illustrates an exemplary methodology 1500 for wound healing and closure in accordance with various embodiments of the present invention. A wound that includes an undermined portion and a surface portion is surgically prepared for negative pressure wound therapy (step 1502). A wound closure device is configured including a compression device, a drainage element, and a port or inlet (step 1504). For example, the compression device can be a bladder 1010 as described previously herein. The wound closure device is placed into the wound (step 1506). Negative pressure is applied at the inlet to cause the bladder to exert pressure on a surface of the tissue (step 1508). The pressure exerted by the bladder causes the undermined portion of the wound to close before the surface portion. The wound is drained of fluids through the drainage element during movement of the wound margins (step 1510). The wound closure device is removed from the wound, and the wound is closed with or without sutures (step 1512).



FIG. 20 illustrates an exemplary methodology 1700 for wound healing and closure in accordance with various embodiments of the present invention. A wound in a tissue that includes an undermined portion and a surface portion is surgically prepared for negative pressure wound therapy (step 1702). A wound closure device including a compression device, a drainage element, and a port or inlet is configured (step 1704). The drainage element is collapsible in the horizontal and vertical directions. An exemplary compression device can include a bladder 1010 as described previously herein. A surgical drain device is configured (step 1706). The surgical drain device and the wound closure device are placed into the wound (step 1708). The surgical drain device is placed ahead of the wound closure device and the surgical drain device and wound closure device are in contact after placement. Negative pressure is applied at the inlet to cause the compression device to exert pressure on the wound and a surface of the tissue surrounding the wound (step 1710). The pressure exerted by the compression device collapses the drainage element of the wound closure device in the vertical and horizontal directions to approximate wound margins in the undermined portion and wound margins at the surface portion, respectively. The wound is drained of fluids during movement of the wound margins (step 1712). The wound closure device is removed from the wound, and the wound is closed with or without sutures (step 1714). A portion of the surgical drain device remains in the closed wound.


While the present inventive concepts have been described with reference to particular embodiments, those of ordinary skill in the art will appreciate that various substitutions and/or other alterations may be made to the embodiments without departing from the spirit of the present inventive concepts. Accordingly, the foregoing description is meant to be exemplary and does not limit the scope of the present inventive concepts.


A number of examples have been described herein. Nevertheless, it should be understood that various modifications may be made. For example, suitable results may be achieved if the described techniques are performed in a different order and/or if components in a described system, device, or method are combined in a different manner and/or replaced or supplemented by other components or their equivalents. Accordingly, other implementations are within the scope of the present inventive concepts.

Claims
  • 1. A negative pressure wound closure device to treat a wound comprising; a collapsible structure positionable external to a wound opening, the collapsible structure having a curved contour that is configured to extend over at least a portion of tissue adjacent to the wound opening, the collapsible structure having articulating elements defining a plurality of cells allowing fluid flow from the wound opening through each of the plurality of cells, the articulating elements displaced along an arcuate path such that at least some of the plurality of cells contract in size during movement of spaced apart wound margins within the wound opening; anda port in fluid communication with the collapsible structure that is connectable to a negative pressure source such that a negative pressure is applied to remove fluid from the wound opening through one or more of the plurality of cells and to impart a force to the spaced apart wound margins operable to move the wound margins to a more closed position.
  • 2. The device of claim 1 further comprising a flap having a first portion and a second portion.
  • 3. The device of claim 2 wherein the first portion of the flap is relatively more elastic than the second portion of the flap.
  • 4. The device of claim 2 wherein the flap is attached to a wrap using a first plurality of anchoring elements.
  • 5. The device of claim 1 wherein the collapsible structure further comprises a compression element including a stiff edge configured to contact the portion of tissue adjacent the wound opening.
  • 6. The device of claim 1 further comprising a drape configured to attach a lateral portion of the collapsible structure to tissue surrounding a shallow portion of the wound and a deep portion of the wound.
  • 7. The device of claim 6 wherein the force imparted by the collapsible structure on the deep portion is greater than a force imparted on the shallow portion of the wound.
  • 8. The device of claim 7 wherein the negative pressure applied causes the collapsible structure to at least partially collapse, the lateral portion being configured to apply an inward force to the deep portion of the wound that comprises an amputation wound to close before the shallow portion.
  • 9. The device of claim 1 wherein a radius of curvature of the collapsible structure is configured to have a different radius of curvature relative to the tissue surrounding the wound.
  • 10. The device of claim 1 wherein the collapsible structure comprises sliding elements.
  • 11. The device of claim 1 further comprising a foam connected to the collapsible structure.
  • 12. The device of claim 1 wherein the device comprises a sutureless wound closure device.
  • 13. The device of claim 1 wherein the plurality of cells contract in size preferentially along a first arcuate direction relative to a second arcuate direction.
  • 14. The device of claim 1 wherein the collapsible structure has at least a partially domed shape.
  • 15. The device of claim 1 wherein the collapsible structure has an inner surface radius and an outer surface radius.
  • 16. A negative pressure wound closure device to treat an amputation wound comprising: a collapsible structure positionable external to an amputation wound, the collapsible structure having articulating elements defining a plurality of cells configured to allow fluid flow from a wound opening of the amputation wound through each of the plurality of cells, the articulating elements undergoing rotational movement along an arcuate path such that at least some of the plurality of cells contract in size during closure of wound margins within the amputation wound;a negative pressure source in fluid communication with a wound cavity within the amputation wound such that fluid is removed from the wound cavity through one or more of the plurality of cells and wherein a compressive force is imparted to tissue on at least a portion of tissue adjacent to the wound opening of the amputation wound that is coupled to the collapsible structure.
  • 17. The device of claim 16 further comprising flaps attached to the collapsible structure that are configured to attach to the portion of tissue, the amputation wound having a deep portion and a shallow portion.
  • 18. The device of claim 17 wherein the negative pressure imparts the compressive force with the collapsible structure to at least partially collapse the structure thereby causing the deep portion of the amputation wound to close before the shallow portion.
  • 19. The device of claim 16 further comprising a port in the collapsible structure that connects to the negative pressure source.
  • 20. The device of claim 16 wherein the articulating elements rotate at joints to cause the collapsible structure to collapse along the arcuate path above the wound opening.
  • 21. The device of claim 16 further comprising a drain element positionable within the wound opening during wound closure to drain fluid from the wound.
  • 22. The device of claim 21 wherein the drain element comprises drain channels or drain tubes.
  • 23. The device of claim 22 wherein the drain element further comprises a layer of biodegradable material having a plurality of spaced apertures.
RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application 62/267,728 filed Dec. 15, 2015, the entire contents of which is incorporated herein by reference.

US Referenced Citations (359)
Number Name Date Kind
3194239 Sullivan Jul 1965 A
5415715 Delage et al. May 1995 A
5636643 Argenta et al. Jun 1997 A
5960497 Castellino et al. Oct 1999 A
6080168 Levin et al. Jun 2000 A
6086591 Bojarski Jul 2000 A
6142982 Hunt et al. Nov 2000 A
6471715 Weiss Oct 2002 B1
6500112 Khouri Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6641575 Lonky Nov 2003 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6712830 Esplin Mar 2004 B2
6767334 Randolph Jul 2004 B1
6770794 Fleischmann Aug 2004 B2
6814079 Heaton et al. Nov 2004 B2
6893452 Jacobs May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7025755 Epstein Apr 2006 B2
7070584 Johnson et al. Jul 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128735 Weston Oct 2006 B2
7144390 Hannigan et al. Dec 2006 B1
7153312 Torrie et al. Dec 2006 B1
7156862 Jacobs et al. Jan 2007 B2
7172615 Morriss et al. Feb 2007 B2
7189238 Lombardo et al. Mar 2007 B2
7196054 Drohan et al. Mar 2007 B1
7198046 Argenta et al. Apr 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7262174 Jiang et al. Aug 2007 B2
7279612 Heaton et al. Oct 2007 B1
7315183 Hinterscher Jan 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7367342 Butler May 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7413571 Zamierowski Aug 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7494482 Orgill et al. Feb 2009 B2
7534240 Johnson May 2009 B1
7540848 Hannigan et al. Jun 2009 B2
7553306 Hunt et al. Jun 2009 B1
7553923 Williams et al. Jun 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7578532 Schiebler Aug 2009 B2
D602583 Pidgeon et al. Oct 2009 S
7611500 Lina et al. Nov 2009 B1
7615036 Joshi et al. Nov 2009 B2
7618382 Vogel et al. Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645269 Zamierowski Jan 2010 B2
7651484 Heaton et al. Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678102 Heaton Mar 2010 B1
7683667 Kim Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7699831 Bengtson et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7713743 Villanueva et al. May 2010 B2
7722528 Amal et al. May 2010 B2
7723560 Lockwood et al. May 2010 B2
7754937 Boehringer et al. Jul 2010 B2
7776028 Miller et al. Aug 2010 B2
7777522 Yang et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
D625801 Pidgeon et al. Oct 2010 S
7815616 Boehringer et al. Oct 2010 B2
7820453 Heylen et al. Oct 2010 B2
7846141 Weston Dec 2010 B2
7857806 Karpowicz et al. Dec 2010 B2
7896856 Petrosenko et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7942866 Radl et al. May 2011 B2
7951124 Boehringer et al. May 2011 B2
7976519 Bubb et al. Jul 2011 B2
7981098 Boehringer et al. Jul 2011 B2
8030534 Radl et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062295 McDevitt et al. Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8070773 Zamierowski Dec 2011 B2
8080702 Blott et al. Dec 2011 B2
8100887 Weston et al. Jan 2012 B2
8114126 Heaton et al. Feb 2012 B2
8123781 Zamierowski Feb 2012 B2
8128615 Blott et al. Mar 2012 B2
8129580 Wilkes et al. Mar 2012 B2
8142419 Heaton et al. Mar 2012 B2
8162909 Blott et al. Apr 2012 B2
8172816 Kazala, Jr. et al. May 2012 B2
8182413 Browning May 2012 B2
8187237 Seegert May 2012 B2
8188331 Barta May 2012 B2
8197467 Heaton et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8215929 Shen et al. Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8246590 Hu et al. Aug 2012 B2
8273105 Cohen et al. Sep 2012 B2
8353931 Stopek et al. Jan 2013 B2
8376972 Fleischmann Feb 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8444392 Turner et al. May 2013 B2
8444611 Wilkes et al. May 2013 B2
8447375 Shuler May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8460257 Locke et al. Jun 2013 B2
8481804 Timothy Jul 2013 B2
8486032 Seegert et al. Jul 2013 B2
8500704 Boehringer et al. Aug 2013 B2
8500776 Ebner Aug 2013 B2
8523832 Seegert Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8562576 Hu Oct 2013 B2
8608776 Coward et al. Dec 2013 B2
8622981 Hartwell et al. Jan 2014 B2
8628505 Weston Jan 2014 B2
8632523 Eriksson et al. Jan 2014 B2
8679080 Kazala, Jr. et al. Mar 2014 B2
8679153 Dennis Mar 2014 B2
8680360 Greener et al. Mar 2014 B2
8708984 Robinson et al. Apr 2014 B2
8715256 Greener May 2014 B2
8721629 Hardman et al. May 2014 B2
8747375 Barta et al. Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8791315 Lattimore et al. Jul 2014 B2
8791316 Greener Jul 2014 B2
8802916 Griffey et al. Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8821535 Greener Sep 2014 B2
8843327 Vemon-Harcourt et al. Sep 2014 B2
8882730 Zimnitsky et al. Nov 2014 B2
8936618 Sealy et al. Jan 2015 B2
8945030 Weston Feb 2015 B2
8951235 Allen et al. Feb 2015 B2
9050398 Armstrong et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9180231 Greener Nov 2015 B2
9220822 Hartwell Dec 2015 B2
9226737 Dunn Jan 2016 B2
9301742 Dunn Apr 2016 B2
9421132 Dunn Aug 2016 B2
9597484 Dunn Mar 2017 B2
20010029956 Argenta et al. Oct 2001 A1
20020022861 Jacobs et al. Feb 2002 A1
20020077661 Saadat Jun 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030065360 Jacobs et al. Apr 2003 A1
20030108587 Orgill et al. Jun 2003 A1
20030114816 Underhill et al. Jun 2003 A1
20030114818 Benecke et al. Jun 2003 A1
20030114821 Underhill et al. Jun 2003 A1
20030120249 Wulz et al. Jun 2003 A1
20030121588 Pargass et al. Jul 2003 A1
20030220660 Kortenbach et al. Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040010275 Jacobs et al. Jan 2004 A1
20040054346 Zhu et al. Mar 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040147465 Jiang et al. Jul 2004 A1
20040162512 Liedtke et al. Aug 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050119694 Jacobs et al. Jun 2005 A1
20050182445 Zamierowski Aug 2005 A1
20050209574 Boehringer et al. Sep 2005 A1
20050222544 Weston Oct 2005 A1
20050222613 Ryan Oct 2005 A1
20050240220 Zamierowski Oct 2005 A1
20050258887 Ito et al. Nov 2005 A1
20060058842 Wilke et al. Mar 2006 A1
20060064124 Zhu et al. Mar 2006 A1
20060069357 Marasco Mar 2006 A1
20060079599 Arthur Apr 2006 A1
20060135921 Wiercinski et al. Jun 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060257457 Gorman et al. Nov 2006 A1
20060259074 Kelleher et al. Nov 2006 A1
20070032755 Walsh Feb 2007 A1
20070032763 Vogel Feb 2007 A1
20070038172 Zamierowski Feb 2007 A1
20070052144 Knirck et al. Mar 2007 A1
20070118096 Smith et al. May 2007 A1
20070123816 Zhu et al. May 2007 A1
20070149910 Zocher Jun 2007 A1
20070185463 Mulligan Aug 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070282309 Bengtson et al. Dec 2007 A1
20070282374 Sogard et al. Dec 2007 A1
20070299541 Chernomorsky et al. Dec 2007 A1
20080041401 Casola et al. Feb 2008 A1
20080108977 Heaton et al. May 2008 A1
20080167593 Fleischmann Jul 2008 A1
20080177253 Boehringer et al. Jul 2008 A1
20080275409 Kane et al. Nov 2008 A1
20080287973 Aster et al. Nov 2008 A1
20090005716 Abuzaina et al. Jan 2009 A1
20090005744 Karpowicz et al. Jan 2009 A1
20090018578 Wilke et al. Jan 2009 A1
20090018579 Wilke et al. Jan 2009 A1
20090043268 Eddy et al. Feb 2009 A1
20090069760 Finklestein Mar 2009 A1
20090069904 Picha Mar 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090099519 Kaplan Apr 2009 A1
20090105670 Bentley et al. Apr 2009 A1
20090131888 Joshi May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090227938 Fasching et al. Sep 2009 A1
20090246238 Gorman et al. Oct 2009 A1
20090259203 Hu Oct 2009 A1
20090299255 Kazala, Jr. Dec 2009 A1
20090299256 Barta Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20090299307 Barta Dec 2009 A1
20090299341 Kazala, Jr. Dec 2009 A1
20090299342 Cavanaugh, II Dec 2009 A1
20100022972 Lina et al. Jan 2010 A1
20100022990 Karpowicz et al. Jan 2010 A1
20100028407 Del Priore et al. Feb 2010 A1
20100030132 Niezgoda et al. Feb 2010 A1
20100036333 Schenk, III et al. Feb 2010 A1
20100087854 Stopek et al. Apr 2010 A1
20100100022 Greener et al. Apr 2010 A1
20100100063 Joshi et al. Apr 2010 A1
20100106184 Coward et al. Apr 2010 A1
20100121286 Locke et al. May 2010 A1
20100121287 Smith et al. May 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100137890 Martinez et al. Jun 2010 A1
20100160874 Robinson et al. Jun 2010 A1
20100160876 Robinson et al. Jun 2010 A1
20100160901 Hu et al. Jun 2010 A1
20100179515 Swain et al. Jul 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100256672 Weinberg Oct 2010 A1
20100262126 Hu Oct 2010 A1
20100280468 Haggstrom et al. Nov 2010 A1
20100292717 Petter-Puchner et al. Nov 2010 A1
20100305490 Coulthard et al. Dec 2010 A1
20100318046 Boehringer et al. Dec 2010 A1
20110004173 Hu Jan 2011 A1
20110009838 Greener Jan 2011 A1
20110015594 Hu et al. Jan 2011 A1
20110054283 Shuler Mar 2011 A1
20110054365 Greener Mar 2011 A1
20110060204 Weston Mar 2011 A1
20110066096 Svedman Mar 2011 A1
20110077605 Karpowicz et al. Mar 2011 A1
20110105963 Hu May 2011 A1
20110106026 Wu May 2011 A1
20110130774 Criscuolo et al. Jun 2011 A1
20110172760 Anderson Jul 2011 A1
20110178451 Robinson et al. Jul 2011 A1
20110213287 Lattimore et al. Sep 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110224632 Zimnitsky et al. Sep 2011 A1
20110224634 Locke et al. Sep 2011 A1
20110236460 Stopek et al. Sep 2011 A1
20110238026 Zhang et al. Sep 2011 A1
20110238095 Browning Sep 2011 A1
20110238110 Wilke et al. Sep 2011 A1
20110245682 Robinson et al. Oct 2011 A1
20110245788 Marquez Canada Oct 2011 A1
20110264138 Avelar et al. Oct 2011 A1
20110270201 Bubb Nov 2011 A1
20110275964 Greener Nov 2011 A1
20110282136 Browning Nov 2011 A1
20110282309 Adie Nov 2011 A1
20110282310 Boehringer et al. Nov 2011 A1
20110313374 Lockwood et al. Dec 2011 A1
20120004631 Hartwell Jan 2012 A9
20120010637 Stopek et al. Jan 2012 A1
20120016321 Wu Jan 2012 A1
20120016322 Coulthard et al. Jan 2012 A1
20120029449 Khosrowshahi Feb 2012 A1
20120035560 Eddy et al. Feb 2012 A1
20120041402 Greener Feb 2012 A1
20120059399 Hoke et al. Mar 2012 A1
20120059412 Fleischmann Mar 2012 A1
20120065664 Avitable et al. Mar 2012 A1
20120071841 Bengtson Mar 2012 A1
20120083755 Lina et al. Apr 2012 A1
20120095426 Visscher et al. Apr 2012 A1
20120109188 Viola May 2012 A1
20120121556 Fraser et al. May 2012 A1
20120123358 Hall et al. May 2012 A1
20120136326 Croizat et al. May 2012 A1
20120136328 Johannison et al. May 2012 A1
20120143113 Robinson et al. Jun 2012 A1
20120143158 Yang et al. Jun 2012 A1
20120144989 Du Plessis et al. Jun 2012 A1
20120150078 Chen et al. Jun 2012 A1
20120150133 Heaton et al. Jun 2012 A1
20120157942 Weston Jun 2012 A1
20120165764 Allen et al. Jun 2012 A1
20120172778 Rastegar et al. Jul 2012 A1
20120172926 Hotter Jul 2012 A1
20120191054 Kazala, Jr. et al. Jul 2012 A1
20120197415 Montanari et al. Aug 2012 A1
20120203189 Barta Aug 2012 A1
20120209226 Simmons et al. Aug 2012 A1
20120209227 Dunn Aug 2012 A1
20120220968 Confalone et al. Aug 2012 A1
20120222687 Czajka, Jr. et al. Sep 2012 A1
20120277773 Sargeant et al. Nov 2012 A1
20120302440 Theliander et al. Nov 2012 A1
20130096518 Hall et al. Apr 2013 A1
20130110058 Adie et al. May 2013 A1
20130131564 Locke et al. May 2013 A1
20130138054 Fleischmann May 2013 A1
20130150814 Buan Jun 2013 A1
20130197457 Kazala, Jr. et al. Aug 2013 A1
20130245527 Croizat et al. Sep 2013 A1
20130253401 Locke et al. Sep 2013 A1
20130274717 Dunn Oct 2013 A1
20130310781 Phillips et al. Nov 2013 A1
20130317465 Seegert Nov 2013 A1
20130331757 Belson Dec 2013 A1
20140066868 Freedman et al. Mar 2014 A1
20140068914 Coward et al. Mar 2014 A1
20140088455 Christensen et al. Mar 2014 A1
20140094730 Greener Apr 2014 A1
20140180225 Dunn Jun 2014 A1
20140194836 Kazala, Jr. et al. Jul 2014 A1
20140194837 Robinson et al. Jul 2014 A1
20140213994 Hardman et al. Jul 2014 A1
20140228789 Wilkes et al. Aug 2014 A1
20140336602 Karpowicz et al. Nov 2014 A1
20140343517 Jameson Nov 2014 A1
20150005722 Hu Jan 2015 A1
20150025484 Simmons et al. Jan 2015 A1
20150065968 Sealy et al. Mar 2015 A1
20150080947 Greener Mar 2015 A1
20150112290 Dunn Apr 2015 A1
20150112311 Hammond et al. Apr 2015 A1
20150119865 Barta et al. Apr 2015 A1
20150148760 Dodd et al. May 2015 A1
20150150729 Dagger Jun 2015 A1
20150159066 Hartwell et al. Jun 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150190288 Dunn et al. Jul 2015 A1
20150196431 Dunn et al. Jul 2015 A1
20150320602 Locke et al. Nov 2015 A1
20160278773 Dunn Sep 2016 A1
20160354086 Dunn Dec 2016 A1
20170165116 Dunn Jun 2017 A1
20170281838 Dunn Oct 2017 A1
Foreign Referenced Citations (90)
Number Date Country
2012261793 Jan 2013 AU
101112326 Jan 2008 CN
2949920 Mar 1981 DE
102012001752 Aug 2013 DE
1320342 Jun 2003 EP
2094211 Sep 2009 EP
2279016 Feb 2011 EP
2341955 Jul 2011 EP
2366721 Sep 2011 EP
2367517 Sep 2011 EP
2368523 Sep 2011 EP
2404571 Jan 2012 EP
2404626 Jan 2012 EP
2563421 Mar 2013 EP
2567717 Mar 2013 EP
2594299 May 2013 EP
2601984 Jun 2013 EP
2623137 Aug 2013 EP
2389794 Dec 2003 GB
2423019 Aug 2006 GB
2496310 May 2013 GB
20140129 Mar 2016 IE
200189392 Nov 2001 WO
200205737 Jan 2002 WO
2003003948 Jan 2003 WO
2004018020 Mar 2004 WO
2006041496 Apr 2006 WO
2006046060 May 2006 WO
2006087021 Aug 2006 WO
2008064502 Jun 2008 WO
2008104609 Sep 2008 WO
2009019495 Feb 2009 WO
2009071926 Jun 2009 WO
2009071933 Jun 2009 WO
2009112062 Sep 2009 WO
2009112848 Sep 2009 WO
2009114624 Sep 2009 WO
WO 2009112848 Sep 2009 WO
WO 2009114624 Sep 2009 WO
2009156709 Dec 2009 WO
WO 2009158125 Dec 2009 WO
2010033725 Mar 2010 WO
2010059612 May 2010 WO
2010075180 Jul 2010 WO
2010078349 Jul 2010 WO
2010079359 Jul 2010 WO
2010092334 Aug 2010 WO
2010097570 Sep 2010 WO
2011023384 Mar 2011 WO
2011087871 Jul 2011 WO
2011091169 Jul 2011 WO
2011106722 Sep 2011 WO
2011115908 Sep 2011 WO
2011135286 Nov 2011 WO
2011135287 Nov 2011 WO
2011137230 Nov 2011 WO
2012021553 Feb 2012 WO
2012038727 Mar 2012 WO
2012082716 Jun 2012 WO
2012082876 Jun 2012 WO
2012087376 Jun 2012 WO
2012106590 Aug 2012 WO
2012112204 Aug 2012 WO
2012136707 Oct 2012 WO
2012142473 Oct 2012 WO
2012156655 Nov 2012 WO
2012168678 Dec 2012 WO
2013012381 Jan 2013 WO
2013007973 Jan 2013 WO
2013043258 Mar 2013 WO
2013071243 May 2013 WO
2013074829 May 2013 WO
2013079947 Jun 2013 WO
2013175309 Nov 2013 WO
2013175310 Nov 2013 WO
2014013348 Jan 2014 WO
2014014842 Jan 2014 WO
2014014871 Jan 2014 WO
2014014922 Jan 2014 WO
2014024048 Feb 2014 WO
2014140578 Sep 2014 WO
2014158526 Oct 2014 WO
2014165275 Oct 2014 WO
2015008054 Jan 2015 WO
2015061352 Apr 2015 WO
2015109359 Jul 2015 WO
2015110409 Jul 2015 WO
2015110410 Jul 2015 WO
2016184913 Nov 2016 WO
2017063036 Apr 2017 WO
Non-Patent Literature Citations (12)
Entry
Epstein et al., Lipoabdominoplasty Without Drains or Progressive Tension Sutures: An Analysis of 100 Consecutive Patients. Aesthetic Surgery Journal. Apr. 2015;35(4):434-440.
Hougaard et al., The open abdomen: temporary closure with a modified negative pressure therapy technique. Int Wound J. Jun. 2014;11 Suppl 1:13-6.
International Preliminary Report on Patentability by the International Bureau of WIPO for International Patent Application No. PCT/US2016/067051 dated Jun. 19, 2018.
Kapischke et al., Self-fixating mesh for the Lichtenstein procedure—a prestudy. Langenbecks Arch Surg. Apr. 2010;395(4):317-22.
Macias et al., Decrease in Seroma Rate After Adopting Progressive Tension Sutures Without Drains: A Single Surgery Center Experience of 451 Abdominoplasties over 7 Years. Aesthetic Surgery Journal. Mar. 2016;36(9)1029-1035.
Pollock et al., Progressive Tension Sutures in Abdominoplasty: A Review of 597 Consecutive Cases. Aesthetic Surgery Journal. Aug. 2012;32(6):729-742.
Quaba et al., The no-drain, no-quilt abdominoplasty: a single-surgeon series of 271 patients. Plast Reconstr Surg. Mar. 2015;135(3):751-60.
Rothenberg et al., Emerging Insights On Closed Incision NPWT And Transmetatarsal Amputations. http://www.podiatrytoday.com/emerging-insights-closed-incision-npwt-and-transmetatarsal-amputations. Apr. 2015;28(4):1-5.
International Search Report and Written Opinion for Application No. PCT/US2018/038851, dated Jan. 15, 2019, 19 pages.
Supplementary European Search Report for Application No. 16876731.7, dated May 7, 2019, 8 pages.
Bengezi et al., Elevation as a treatment for fasciotomy wound closure. Can J Plast Surg. 2013 Fall;21(3):192-4.
Jauregui et al., Fasciotomy closure techniques. J Orthop Surg (Hong Kong). Jan. 2017;25(1):2309499016684724. 8 pages.
Related Publications (1)
Number Date Country
20170165116 A1 Jun 2017 US
Provisional Applications (1)
Number Date Country
62267728 Dec 2015 US